Results 61 to 70 of about 1,389,538 (204)
Comparative analysis of virtual screening approaches in the search for novel EphA2 receptor antagonists [PDF]
The EphA2 receptor and its ephrin-A1 ligand form a key cell communication system, which has been found overexpressed in many cancer types and involved in tumor growth.
PALA, Daniele +16 more
core +1 more source
Summary The world‐wide prevalence of insomnia disorder reaches up to 10% of the adult population. Women are more often afflicted than men, and insomnia disorder is a risk factor for somatic and mental illness, especially depression and anxiety disorders.
Dieter Riemann +13 more
wiley +1 more source
Orexin receptors in GtoPdb v.2025.3 [PDF]
Orexin receptors (nomenclature as agreed by the NC-IUPHAR Subcommittee on Orexin receptors [79]) are activated by the endogenous polypeptides orexin-A and orexin-B (also known as hypocretin-1 and -2; 33 and 28 aa) derived from a common precursor, prepro-
de Lecea, Luis +17 more
core +1 more source
Summary Parasomnias and sleep‐related movement disorders (SRMD) are major causes of sleep disorders and may be drug induced. The objective of this study was to conduct a systematic review of the literature to examine the association between drug use and the occurrence of parasomnias and SRMD.
Sylvain Dumont +5 more
wiley +1 more source
Orexins are recently found to participate in mediating stress-induced drug relapse. However, the neuroanatomical basis that orexin transmission modulates stress-induced drug seeking remains unknown. The nucleus accumbens shell (NAcSh), best known for its
Keke eQi +4 more
doaj +1 more source
Discovery of 1H-pyrazolo[3,4-b]pyridines as potent dual orexin receptor antagonists (DORAs)
Compound rac-1 was identified by high throughput screening. Here we report SAR studies and MedChem optimization towards the highly potent dual orexin receptor antagonists (S)-2 and (S)-3. Furthermore, strategies to overcome the suboptimal physicochemical
Gee, Christine +14 more
core +1 more source
Lemborexant 10 mg, a dual orexin‐receptor antagonist (DORA), did not elicit respiratory depressant effects, as measured by peripheral oxygen saturation (SpO2) or apnea–hypopnea index (AHI), in subjects with moderate‐to‐severe chronic obstructive pulmonary disease (COPD).
Jocelyn Y. Cheng +3 more
wiley +1 more source
Orexin 2 receptor agonists have demonstrated that targeting the orexin system may address symptoms of central disorders of hypersomnolence. Results of this phase 1 study support the phase 2 clinical evaluation of oral alixorexton in patients with IH, NT2 and NT1.
Ronald R. Grunstein +10 more
wiley +1 more source
Daridorexant‐ Case Report of Possible Side‐Effect in Rare Mitochondrial Disorder
ABSTRACT This case report describes a 40‐year‐old woman with maternally inherited diabetes and deafness (MIDD), a rare mitochondrial disorder, who received treatment with daridorexant due to severe chronic insomnia. She developed progression of her MIDD symptoms during treatment.
Sven Svedmyr, Joel Bergqvist
wiley +1 more source
Evidence for orexinergic mechanisms in migraine
Objective: To examine the effect of the orexinergic blockade with a dual orexin receptor antagonist (DORA) on experimental models of peripheral and central trigeminal as well as cortical activation relevant to migraine and migraine aura. Methods: In this
Jan Hoffmann +7 more
doaj +1 more source

